2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b Open-Label Repeat Kidney Biopsy Study Sibeprenlimab - IgA Nephropathy | Phase 2 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 56 | 2024-12-05 | 2026-10-27 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
Glomerulonephritis, IGA (2) · Diabetic Nephropathies (1) · Glomerulosclerosis, Focal Segmental (1) · Nephritis, Hereditary (1)
Autoimmune Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Nephritis (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Collagen Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Diabetes Complications (1)
Atrasentan (1)
Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
United Kingdom (2) · United States (2) · Argentina (1) · Australia (1) · Canada (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1)